Trial · NCT00510783
IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
NCT00510783, Phase 4, Completed, Emory University; results first posted 2013-08-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures. Trials, record NCT00510783. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00510783
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures
- NCT number
- NCT00510783
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 158 participants, actual
- Lead sponsor
- Emory University
- Conditions
- Tonic-clonic Seizure
- Interventions
- Keppra, Fosphenytoin, Dilantin
- First posted
- 2007-08-02
- Last updated
- 2013-12-12
- Results first posted
- 2013-08-05
- Limitations and caveats
- Several patients were lost to follow-up.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Who Experienced a Recurrent Seizure After Treatment. | 24 hours | Recurrent seizure is defined as a seizure within 24 hours of treatment in the Emergency Department. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Who Experienced a Recurrent Seizure After Treatment. | 24 hours | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a Recurrent Seizure After Treatment. | Phenytoin/Fosphenytoin | 2 | participants | ||
| Number of Participants Who Experienced a Recurrent Seizure After Treatment. | Levetiracetam | 3 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Phenytoin/Fosphenytoin | 82 | |
| Overall Study | STARTED | Levetiracetam | 76 | |
| Overall Study | COMPLETED | Phenytoin/Fosphenytoin | 51 | |
| Overall Study | COMPLETED | Levetiracetam | 47 | |
| Overall Study | NOT COMPLETED | Phenytoin/Fosphenytoin | 31 | |
| Overall Study | NOT COMPLETED | Levetiracetam | 29 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | Investigations | Phenytoin/Fosphenytoin | 4 | 82 | 4 |
| other | Fatigue | Investigations | Levetiracetam | 7 | 76 | 7 |
| other | Burning at the IV Site | Investigations | Phenytoin/Fosphenytoin | 11 | 82 | 15 |
| other | Burning at the IV Site | Investigations | Levetiracetam | 5 | 76 | 5 |
| other | Itching | Investigations | Phenytoin/Fosphenytoin | 8 | 82 | 8 |
| other | Itching | Investigations | Levetiracetam | 0 | 76 | 0 |
| other | Dizziness | Investigations | Phenytoin/Fosphenytoin | 17 | 82 | 17 |
| other | Dizziness | Investigations | Levetiracetam | 7 | 76 | 7 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Phenytoin/Fosphenytoin | ||
| Total, all-cause mortality | Levetiracetam | ||
| Total, other adverse events | Phenytoin/Fosphenytoin | 40 | 82 |
| Total, other adverse events | Levetiracetam | 19 | 76 |
| Total, serious adverse events | Phenytoin/Fosphenytoin | 0 | 82 |
| Total, serious adverse events | Levetiracetam | 0 | 76 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Phenytoin/Fosphenytoin vs Levetiracetam: Number of Participants Who Experienced a Recurrent Seizure After Treatment. | Trial comparisons |
| Phenytoin/Fosphenytoin vs Levetiracetam: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00510783
GET https://conductscience.org/api/trials/v1/NCT00510783/registered